The development of immune-checkpoint inhibitors (ICIs) has heralded a new era in cancer
treatment, enabling the possibility of long-term survival in patients with metastatic disease …

Protein kinases regulate nearly all aspects of cell life, and alterations in their expression, or
mutations in their genes, cause cancer and other diseases. Here, we review the remarkable …

Background Checkpoint inhibitors are standard adjuvant treatment for stage IIB–IV resected
melanoma, but many patients recur. Our study aimed to evaluate whether mRNA-4157 …

Abstract The United States Food and Drug Administration (US FDA) has always been a
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …

Drug-tolerant persister (DTP) cell populations were originally discovered in antibiotic-
resistant bacterial biofilms. Similar populations with comparable features have since been …

Background In the previously reported primary analyses of this phase 3 trial, 12 months of
adjuvant pembrolizumab resulted in significantly longer recurrence-and distant metastasis …

No prospective data were available prior to 2021 to inform selection between combination
BRAF and MEK inhibition versus dual blockade of programmed cell death protein-1 (PD-1) …

In June 2022, the FDA granted Accelerated Approval to the BRAF inhibitor dabrafenib in
combination with the MEK inhibitor trametinib for the treatment of adult and paediatric …

Background The IMMUNED trial previously showed significant improvements in recurrence-
free survival for adjuvant nivolumab plus ipilimumab as well as for adjuvant nivolumab alone …

Purpose: In the phase III CheckMate 238 study, adjuvant nivolumab significantly improved
recurrence-free survival (RFS) and distant metastasis-free survival versus ipilimumab in …